Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Takeda UK Limited, 1 Kingdom Street, London, W2 6BD, United Kingdom
Condyline 5 mg/ml Cutaneous Solution.
| Pharmaceutical Form |
|---|
|
Cutaneous Solution. Each pack of Condyline consists of a 3.5 ml amber glass vial containing 5 mg/ml podophyllotoxin in a clear, colourless alcoholic solution. |
Condyline contains 5 mg/ml podophyllotoxin in vials of 3.5 ml.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Podophyllotoxin |
Podophyllotoxin is a metaphase inhibitor in dividing cells binding to at least one binding site on tubulin. Binding prevents tubulin polymerisation required for microtubule assembly. At higher concentrations, podophyllotoxin also inhibits nucleoside transport through the cell membrane. |
| List of Excipients |
|---|
|
Lactic acid |
Each pack of Condyline consists of a 3.5ml amber glass vial fitted with a child resistant closure. The pack also includes a suitable quantity of special applicators.
Takeda UK Limited, 1 Kingdom Street, London, W2 6BD, United Kingdom
PL 16189/0037
23 January 2009
| Drug | Countries | |
|---|---|---|
| CONDYLINE | Canada, Estonia, France, Ireland, Netherlands, New Zealand, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
